return equiti ttm
fiscal third quarter impact transient issu look
commerci pipelin execut turn posit
happen report fiscal third-quart result revenu
billion constant currenc street estim billion
manag attribut miss sever transient issuessom oper
associ time product pipelinethough also cite sever
surpris includ market growth tavr diabet two market
particularli well sum number move piec segment came
expect top line though bottom line exceed estim
guidanc appear risk opportun said manag reiter
confid sale would reacceler fourth quarter organ
constant currenc acceler fiscal fiscal
point believ compani need ultim prove abil deliv
new product strategi someth support maintain stabil
mani segment product seem difficult quarter manag allud
oper chang help drive toward goal includ chang incent
heavili weight sale toward backend quarter someth seen
mix result compani done effect believ help outlook
though onu manag ensur add disrupt
manag highlight follow transient issu call neg impact
erp upgrad mtig upgrad complet weaker-than-expect sale
cvg custom wait new product launch weak tavr growth slower-than-
expect ramp-up product november/decemb seem solid follow
weak januari weak custom order infus bone graft rtg
encourag manag quick action address issu segment specif
companywid believ issu especi salesforc pipelin
relat may take sever month take root could even introduc risk
commerci disrupt manag guidanc acceler growth exclud
total sale addit sale growth taken togeth believ on-going
remedi effort coupl coronaviru add risk near-term expect
ep beat highlight quarter said deliv strong adjust
ep ahead street leverag quarter
support benefit compani on-going enterpris excel initi
lower interest expens due debt refinanc better-than-
expect currenc hedg altogeth deliv basi point oper
margin improv exclud currenc benefit reiter long-term guidanc
basi point margin expans annual model basi point
margin improv fiscal believ meet estim
domin player medic technolog sector market-lead franchis product
cardiac rhythm manag spinal cardiovascular neurolog condit diabet surgic technolog
impact coronaviru alreadi neg impact medtron result china
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
coronaviru push procedur despit medtron report growth china quarter end januari
manag cite hospit experienc delay medic devic procedur impact fourth
quarter last week chines govern pull doctor nurs citi sent hubei
provinc provid defici system fear around viru also spread south korea thailand
even japan patient like similarli avoid push procedur manufactur perspect
oper appear unchang far though monitor go forward
context china made total sale quarter though grow market rate manag
expect transient impact top-lin perspect though believ may also impact bottom line medtron
guid organ constant currenc growth fourth quarter fiscal exclud potenti impact
coronaviru manag provid specif detail impact updat estim
includ roughli million neg headwind compani spine brain therapi group bring us
organ constant currenc growth neg ep impact fourth quarter
tavr growth well market third-quart global tavr growth midteen growth
estim manag estim domest market growth rang edward report
impli share loss market compani attribut weak salesforc issu slower-than-expect rep
product ramp-up low headcount result poor procedur coverag experienc rep pull
establish account help open new tavr account believ issu transient point continu
presenc two-third tavr center plan hire addit rep fiscal year-end continu
posit feedback on-going evolut pro-plu next-gen valv roll-out upcom data present support
adopt bicuspid leaflet immobl patient note go holiday compani saw implant rate
rang impli signific slowdown januari though februari sound like might slightli better
come away believ segment perform would improv overnight
overal expect medtron effort help reacceler tavr growth remain cautiou near-term upsid
given need meaning headcount expans time market rapidli grow heel low-risk
approv next-gen product launch experi medic devic compani process
meaning ramp sale headcount disrupt new account settl rep ramp
product perform quarter support thesi though reacceler take coupl quarter look
meaning sign sustain tavr reacceler get posit segment believ
compani might lose market share albeit modestli come quarter
diabet timelin slightli push back reiter pipelin effort third-quart diabet sale flat year-over-year
strong intern growth strong adopt off-set share loss increasingli
competit pump cgm market domest diabet result larg continu
recent trend diabet busi intern strength help off-set weak emphas
compani need next-gen product pump sensor help stabil busi sustain
reacceler segment sale growth
end third-quart call manag provid mix updat diabet product pipelin pump
side next-gen system file ce mark approv fda file slightli delay
march impli earli mid-fisc launch compar late fiscal launch meantim medtron
launch upgrad program encourag patient purchas pump offer new user free upgrad
approved/launch sensor side manag provid meaning updat sean salmon new head
diabet highlight increas confid sensor pipelin immedi focu achiev icgm design
taken togeth believ invest appropri pipelin initi diabet want wait see
execut close competit gap get posit abil acceler go forward pump
updat eventu help fend competit believ cgm still lag behind competit calibr
requir form factor accuraci could impact cgm pump sale time look addit updat
pipelin upcom confer like attd meet februari expect subset data present
product pipelin remain key focu view execut key pipelin product remain key sustain acceler
growth rang manag provid specif product contribut
key product look forward come quarter
cvg tavr compani continu expand low-risk see solid earli adopt next-gener
valv evolut note tavr also benefit new data present march bicuspid
leaflet immobl expand headcount crhf continu anticip launch reveal linq
insert cardiac monitor approv launch micra av transcathet pace system expect
expand elig pacemak market today fiscal first quarter
rtg stealth autoguid cranial robot system start launch fiscal third quarter surescan mri lead
interstim micro mri pelvic health percept pc deep brain stimul next-gener spinal cord
stimul pain therapi expect next quarter
diabet near term launch minim advanc hybrid closed-loop system bluetooth
connect sometim earli fiscal cgm fda submiss expect second half calendar
impli potenti approv first half
mitg manag slightli delay soft issu robot platform timelin expect initi
commerci launch earli fiscal year first intern market follow ce mark submiss
 ide file fiscal first quarter fiscal first half respect unchang
stock thought risk
encourag number catalyst could togeth acceler top-lin growth midsingl digit
wait execut pipelin product demonstr compani abil acceler growth sustain beyond
without activ said core med tech investor may want look share past time
rate market fundament segment remain strong share trade time
calendar ep estim line modestli large-cap peer rate share market perform
risk thesi includ better-than-anticip execut market adopt key pipelin product could acceler
top-lin growth subsequ drive strong share perform bottom line may abl execut greater-
than-anticip cost-sav initi subsequ reach better-than-expect ep drive share momentum
newpreviouschang newpreviouschang cardiac rhythm structur peripher gi growth report growth xfx margin incom tax ep william blair estimatesfisc summari chang model import disclosur
